Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial

Merry Tetef, Lucille Leong, Chul Ahn, Steven Akman, Warren Chow, Kim Margolin, Robert J. Morgan, James Raschko, Stephen Shibata, George Somlo, James H. Doroshow

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.

Original languageEnglish (US)
Pages (from-to)114-117
Number of pages4
JournalCancer Investigation
Volume17
Issue number2
StatePublished - 1999

Fingerprint

Cytarabine
Cisplatin
Adenocarcinoma
Therapeutics
Carcinoma
Colon
Liver

Keywords

  • Cisplatin
  • Colon carcinoma
  • Cytosine arabinoside
  • Phase II trial
  • Rectal carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tetef, M., Leong, L., Ahn, C., Akman, S., Chow, W., Margolin, K., ... Doroshow, J. H. (1999). Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial. Cancer Investigation, 17(2), 114-117.

Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma : A phase II trial. / Tetef, Merry; Leong, Lucille; Ahn, Chul; Akman, Steven; Chow, Warren; Margolin, Kim; Morgan, Robert J.; Raschko, James; Shibata, Stephen; Somlo, George; Doroshow, James H.

In: Cancer Investigation, Vol. 17, No. 2, 1999, p. 114-117.

Research output: Contribution to journalArticle

Tetef, M, Leong, L, Ahn, C, Akman, S, Chow, W, Margolin, K, Morgan, RJ, Raschko, J, Shibata, S, Somlo, G & Doroshow, JH 1999, 'Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial', Cancer Investigation, vol. 17, no. 2, pp. 114-117.
Tetef, Merry ; Leong, Lucille ; Ahn, Chul ; Akman, Steven ; Chow, Warren ; Margolin, Kim ; Morgan, Robert J. ; Raschko, James ; Shibata, Stephen ; Somlo, George ; Doroshow, James H. / Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma : A phase II trial. In: Cancer Investigation. 1999 ; Vol. 17, No. 2. pp. 114-117.
@article{8b656524f7bc44dfad965f285c760472,
title = "Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma: A phase II trial",
abstract = "Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3{\%} (1/32 patients; 95{\%} CI, 0-16{\%}) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.",
keywords = "Cisplatin, Colon carcinoma, Cytosine arabinoside, Phase II trial, Rectal carcinoma",
author = "Merry Tetef and Lucille Leong and Chul Ahn and Steven Akman and Warren Chow and Kim Margolin and Morgan, {Robert J.} and James Raschko and Stephen Shibata and George Somlo and Doroshow, {James H.}",
year = "1999",
language = "English (US)",
volume = "17",
pages = "114--117",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Cisplatin and infusional cytosine arabinoside for the treatment of colorectal adenocarcinoma

T2 - A phase II trial

AU - Tetef, Merry

AU - Leong, Lucille

AU - Ahn, Chul

AU - Akman, Steven

AU - Chow, Warren

AU - Margolin, Kim

AU - Morgan, Robert J.

AU - Raschko, James

AU - Shibata, Stephen

AU - Somlo, George

AU - Doroshow, James H.

PY - 1999

Y1 - 1999

N2 - Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.

AB - Based on the in vitro and in vivo synergy between cytosine arabinoside (Ara-C) and cis-diamminedichloroplatinum (cisplatin), we designed a phase II trial of Ara-C with cisplatin for patients with colorectal adenocarcinoma. Forty-eight eligible patients received continuous infusion Ara-C, 30 mg/m2/day over 72 hr, plus cisplatin, 30 mg/m2 for three doses at hours 12, 36, and 60 of the Ara-C infusion. The objective partial response rate for patients with colon carcinoma was 3% (1/32 patients; 95% CI, 0-16%) with a median response duration of 2.8 months. None of the 16 patients treated for rectal carcinoma responded. Myelosuppression was the most severe toxicity. Significant gastrointestinal and hepatic toxicities occurred in a small number of patients. Nephrotoxicity and neurotoxicity were mild. We conclude that the prolonged infusion of Ara-C in combination with divided doses of cisplatin offers no significant therapeutic advantage.

KW - Cisplatin

KW - Colon carcinoma

KW - Cytosine arabinoside

KW - Phase II trial

KW - Rectal carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0033044754&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033044754&partnerID=8YFLogxK

M3 - Article

C2 - 10071595

AN - SCOPUS:0033044754

VL - 17

SP - 114

EP - 117

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 2

ER -